Article Text

Download PDFPDF
Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women with osteoporosis, is strontium ranelate more effective than placebo for reducing the risk of vertebral fractures?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Geriatrics ★★★★★☆☆ Rheumatology ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients and healthcare providers).*

Embedded ImageFollow up period:

3 years.

Embedded ImageSetting:

72 centres in 11 European countries and Australia.

Embedded ImagePatients:

1649 women who were ⩾50 years of age (mean age 69 y) and had been postmenopausal for ⩾5 years, had ⩾1 fracture confirmed by spinal radiography, and had a lumbar spine bone mineral density (BMD) ⩽0.840 g/cm2. Exclusion criteria were severe diseases or conditions that could interfere with bone metabolism or use of antiosteoporotic treatments (fluoride salts and bisphosphonates, oestrogen, calcitonin, or calcitriol).

Embedded ImageIntervention:

all …

View Full Text


  • * See glossary.

  • For correspondence: Dr P J Meunier, Edouard Herriot Hospital, Lyons, France.

  • Source of funding: Servier.